Pfizer Q3 preview: Where next for the Pfizer share price?

Pfizer’s revenue and earnings have soared thanks to strong demand for its coronavirus vaccine, but there are concerns there could be a significant slowdown in 2022. We explain what to expect and consider how Pfizer shares could react.

Charts (2)

When will Pfizer release Q3 earnings?

Pfizer is scheduled to release third quarter earnings on Tuesday November 2.


Pfizer Q3 earnings preview: what to expect from the results

The Covid-19 vaccine developed by Pfizer, as well as its German partner BioNTech, has transformed the business this year. Pfizer is set to ship 2.1 billion doses of its jabs – one of the most widely-used around the world - this year and reap a staggering $33.5 billion in sales. For context, the rest of Pfizer’s wider business is forecast to generate sales of $44.5 to $46.5 billion.

As orders for the vaccine continue to flood-in, Pfizer has upgraded its guidance on several occasions this year. When it made the last upgrade back in July, it said it is targeting annual 2021 revenue of between $78.0 billion to $80.0 billion with adjusted EPS of $3.95 to $4.05. If achieved, that would deliver impressive growth from the $41.9 billion in revenue and EPS of $2.22 booked in 2020.

Notably, analysts believe Pfizer can beat that guidance with consensus numbers from Bloomberg showing Wall Street is forecasting Pfizer will deliver annual revenue of $81.0 billion and EPS of $4.11, prompted by strong demand for its vaccine. This is a signal in itself that Pfizer could upgrade expectations once again when it releases third quarter earnings.

Wall Street is expecting Pfizer to report revenue of $22.71 billion in the third quarter. That would be up 87% from the $12.13 billion in sales booked the year before, marking a slight acceleration in topline growth from the 86% year-on-year rise reported in the last quarter.

Adjusted EPS is forecast to increase to $1.09 from $0.72 with reported EPS expected to jump to $1.03 from just $0.39 the year before.

There seems little doubt that 2021 will be a blowout year for Pfizer, with demand for its vaccine poised to almost double overall revenue. However, analysts are far more uncertain going into 2022. Vaccine sale estimates for 2022 are wide-ranging, from as low as $9 billion to as high as $34 billion, according to numbers from Bloomberg. The reason for the large gap between forecasts is largely down to the uncertainty over how developed nations will use booster shots going forward and because more sales will shift to lower-and-middle-income countries, where the economics may different. Markets would welcome any update that could allay concerns over vaccine sales next year, although they may have to wait for the fourth quarter earnings to get a full picture.

Pfizer shares are currently trading over 24% higher than pre-pandemic levels but have lost steam since hitting fresh all-time highs in August. The 22 brokers covering the stock currently have a Hold rating on Pfizer but the average target price of $46.45 implies there is over 8% potential upside from the current share price.


Where next for the Pfizer share price?

The Pfizer share price steadily trended higher across the year accelerating the runup to $51.86, the all-time high hit in mid-August. The price then trended lower finding support at $41. 

The price is extending its rebound from $41, the 3-month low, and is attempting to retake the ascending trendline dating back to early March. 

Buyers will be looking for a move over $44 the monthly high and $44.50 the 50 sma in order for bulls to gain traction. 

Meanwhile, sellers are looking for a move below $41 which would expose the 200 sma at $40. Beyond here, the stock could eye $38.50. 

Where next for the Pfizer share price?


How to trade Pfizer shares

You can trade Pfizer shares with City Index in just four easy steps:

  1. Open a City Index account, or log-in if you’re already a customer.
  2. Search for ‘Pfizer’ in our award-winning platform
  3. Choose your position and size, and your stop and limit levels
  4. Place the trade



This report is intended for general circulation only. It should not be construed as a recommendation, or an offer (or solicitation of an offer) to buy or sell any financial products. The information provided does not take into account your specific investment objectives, financial situation or particular needs. Before you act on any recommendation that may be contained in this report, independent advice ought to be sought from a financial adviser regarding the suitability of the investment product, taking into account your specific investment objectives, financial situation or particular needs.

StoneX Financial Pte. Ltd., may distribute reports produced by its respective foreign entities or affiliates within the StoneX group of companies or third parties pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed to a person in Singapore who is not an accredited investor, expert investor or an institutional investor (as defined in the Securities Futures Act), StoneX Financial Pte. Ltd. accepts legal responsibility to such persons for the contents of the report only to the extent required by law. Singapore recipients should contact StoneX Financial Pte. Ltd. at 6826 9988 for matters arising from, or in connection with the report.

In the case of all other recipients of this report, to the extent permitted by applicable laws and regulations neither StoneX Financial Pte. Ltd. nor its associated companies will be responsible or liable for any loss or damage incurred arising out of, or in connection with, any use of the information contained in this report and all such liability is hereby expressly disclaimed. No representation or warranty is made, express or implied, that the content of this report is complete or accurate.

StoneX Financial Pte. Ltd. is not under any obligation to update this report.

Trading CFDs and FX on margin carries a high level of risk that may not be suitable for some investors. Consider your investment objectives, level of experience, financial resources, risk appetite and other relevant circumstances carefully. The possibility exists that you could lose some or all of your investments, including your initial deposits. If in doubt, please seek independent expert advice. Visit for the complete Risk Disclosure Statement.